A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 274 participants.

Also called NCT01713530

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 274 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01713530
  • EudraCT 2012-002346-20
Other papers using this trial's data
  • Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial Diabetes, obesity & metabolism, 2016-03 DOI, PubMed 26592732, PMC5066701 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Algeria, Austria, France, Norway (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01713530. Randomized; no masking; primary purpose treatment. Start 2013-02-21 (actual); primary completion 2014-01-09 (actual). Results posted on 2015-11-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
insulin degludec/insulin aspart
Intervention (Drug)
insulin degludec
Intervention (Drug)
insulin aspart
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct01713530
Content hash
60640c0fb48880d99e14c9166f9ca426f0db3b124386e4e160f9a21d370f5e63